Advertisement
YOU ARE HERE: LAT HomeCollectionsEthyol Drug
IN THE NEWS

Ethyol Drug

FEATURED ARTICLES
BUSINESS
December 13, 1994 | From Times Staff and Wire Reports
FDA Panel Rejects U.S. Bioscience Inc.'s Ethyol: The advisory panel unanimously killed the firm's second attempt to have Ethyol recommended for approval. Ethyol is designed to protect cancer patients from the side effects of chemotherapy. The medical experts assembled by the Food and Drug Administration found that the drug appears to have some biological effect in ovarian cancer patients but not enough to recommend approval. The full FDA generally follows its advisory panels' recommendations.
ARTICLES BY DATE
BUSINESS
December 13, 1994 | From Times Staff and Wire Reports
FDA Panel Rejects U.S. Bioscience Inc.'s Ethyol: The advisory panel unanimously killed the firm's second attempt to have Ethyol recommended for approval. Ethyol is designed to protect cancer patients from the side effects of chemotherapy. The medical experts assembled by the Food and Drug Administration found that the drug appears to have some biological effect in ovarian cancer patients but not enough to recommend approval. The full FDA generally follows its advisory panels' recommendations.
Advertisement
BUSINESS
December 14, 1994 | From Times Staff and Wire Services
Government reports indicating economic expansion with only mild inflation left the bond and stock markets mixed Tuesday. Shorter-term interest rates rose on the assumption that the economy's continued growth makes it likely the Federal Reserve Board will tighten credit again soon. But long-term bond yields, which respond more to the inflation outlook, fell after the government reported that November wholesale inflation was in line with expectations--and apparently under control.
BUSINESS
April 29, 1992 | CHRIS KRAUL, SAN DIEGO COUNTY BUSINESS EDITOR
Wall Street's new skittish attitude toward biotechnology stocks hit hard earlier this month at San Diego's Viagene biotech company. The company, which is developing a therapeutic drug for HIV-positive patients, filed for an initial public offering to raise money for very expensive clinical trials. But later that day, April 15, Viagene's plans were put on hold. Malvern, Pa.
Los Angeles Times Articles
|